Geode Capital Management, LLC Avenue Therapeutics, Inc. Transaction History

Geode Capital Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	BUY	$0.22 - $0.96 $1,456 - $6,355	6,620 Added 8.55%	84,033 $40,000
Q4 2021 Feb 11, 2022	SELL	$0.88 - $1.78 $6,101 - $12,340	-6,933 Reduced 8.22%	77,413 $70,000
Q3 2021 Nov 12, 2021	BUY	$1.48 - $2.65 $7,089 - $12,693	4,790 Added 6.02%	84,346 $125,000
Q2 2021 Aug 13, 2021	SELL	$2.41 - $7.11 $127,821 - $377,100	-53,038 Reduced 40.0%	79,556 $199,000
Q1 2021 May 12, 2021	BUY	$4.7 - $7.17 $34,465 - $52,577	7,333 Added 5.85%	132,594 $804,000
Q4 2020 Feb 12, 2021	BUY	$2.95 - $11.04 $24,263 - $90,804	8,225 Added 7.03%	125,261 $745,000
Q3 2020 Nov 13, 2020	BUY	$9.37 - $12.06 $1,958 - $2,520	209 Added 0.18%	117,036 $1.27 Million
Q2 2020 Aug 13, 2020	BUY	$8.29 - $11.47 $387,242 - $535,786	46,712 Added 66.62%	116,827 $1.26 Million
Q1 2020 May 14, 2020	BUY	$6.44 - $11.32 $14,193 - $24,949	2,204 Added 3.25%	70,115 $626,000
Q4 2019 Feb 13, 2020	BUY	$5.26 - $9.6 $594 - $1,084	113 Added 0.17%	67,911 $651,000
Q2 2019 Aug 14, 2019	BUY	$4.33 - $6.54 $293,565 - $443,398	67,798 New	67,798 $427,000

Ticker ATXI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 4,127,720
Market Cap $9.25M
Description
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was in...

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Geode Capital Management, LLC with notifications on news.